The group's principal activities are to develop novel biopharmaceutical products for the management of serious infections and multi-drug-resistant organisms. The group is currently developing an antimicrobial drug, for the prevention of ventilator-associated pneumonia (vap). Vap is a bacterial pneumonia that can develop in patients receiving mechanical ventilation and is the most common infection occurring in patients in the intensive care unit.
